Recombinant Adeno-Associated Viral Vectors in Plants
Our plant-based AAV production system represents a paradigm shift in gene therapy manufacturing, offering a solution to the prohibitive cost barriers that currently hinder the field.
Technology
Adeno-associated viruses (AAV) have found great popularity for use both in vitro transduction into human cells and in vivo transduction for gene therapy due to their minimal immunogenicity, high efficacy, and relative safety. AAV particles are typically produced in mammalian or insect cell culture systems but maintaining these cell cultures, purification of the AAV particles, and obtaining sufficient viral titers is difficult and expensive. There is a present need for improved methods for producing AAV particles especially due to rising demand for gene therapies in a diverse range of conditions from neurological to metabolic disease. One promising avenue of research is plant-based systems. Plant-based systems offer a promising, cost-effective, and scalable alternative to traditional methods. These systems leverage plant cells to express AAV proteins to enable scalable production with no risk of mammalian virus production. UD Researchers have developed a plant-based system to produce AAV at both a high yield and purity. The system uses Agrobacterium- mediated transient expression in Nicotiana benthamiana . Their lab optimized relative expression of VP1, VP2, and VP3 to achieve efficient capsid assembly and high yield. AAV particle yield levels are comparable to optimized mammalian suspension cultures. Experimental results show that this system achieves AAV6 capsid yields approximately 1000 times higher than previously reported plant-based methods, with yields reaching 1.72 × 1013 particles from just 20 grams of plant tissue. This method is economically feasible with practical scale-up potential and requires simple extraction and purification methods. Preliminary data also demonstrate successful genome packaging into capsids, and functional validation through in vitro transduction and in vivo efficacy testing is actively underway. This plant-based AAV production system addresses the prohibitive cost barriers that currently limit gene therapy accessibility. By achieving significantly higher yields with simplified infrastructure, this technology has the potential to reduce manufacturing costs by 10-100X, making gene therapies economically viable for both established biopharmaceutical manufacturers and emerging gene therapy developers.
Benefits
- Cost Efficiency: Potential to reduce manufacturing costs by 10-100x compared to traditional mammalian cell systems by eliminating bioreactor infrastructure and the need for costly GMP-grade plasmid manufacturing required for direct cell transfection. In the plant system, gene delivery is mediated by Agrobacterium, which carries expression constructs internally.
- Scalability: Production scales with environmentally controlled cultivation area rather than bioreactor capacity, enabling rapid scale-up without capital-intensive facility investment.
- Regulatory Compliance: Eliminates mammalian viral contamination risks and produces negligible endotoxin levels, streamlining the path to regulatory compliance.
- **Accessibility: **Simplified infrastructure lowers barriers for treating rare diseases and smaller patient populations, and enables production in resource-limited settings.
- Flexibility: The transient expression system allows rapid switching between different AAV serotypes and therapeutic transgenes without generating new stable cell lines.
Applications
- Research and Development: Academic institutions and non-profits can leverage this system for gene therapy research and preclinical studies.
- Biopharmaceutical Manufacturing: Enables cost-effective production of gene therapy vectors for clinical trials and treatments.